Epidermal Growth Factor Receptors in Prostate Cancer
Author Information
Author(s): S.Q. Maddy, G.D. Chisholm, A. Busuttil, F.K. Habib
Primary Institution: University Department of Surgery (WGH), Western General Hospital, Edinburgh; Department of Forensic Medicine, University of Edinburgh
Hypothesis
The expression of epidermal growth factor receptors (EGF-R) in human prostate cancer correlates with the histological differentiation of the tumor.
Conclusion
The study found that EGF-R expression is significantly higher in benign prostatic hyperplasia compared to prostate cancer, and varies with the histological grade of the cancer.
Supporting Evidence
- EGF-R levels were significantly higher in benign prostatic hyperplasia than in prostate cancer.
- Well differentiated tumors had higher EGF-R levels compared to poorly differentiated tumors.
- Nine out of 19 cancer specimens showed low or no EGF binding.
Takeaway
This study looked at how a specific protein, EGF-R, behaves in prostate cancer compared to non-cancerous tissue, finding that cancerous tissue has less of this protein.
Methodology
The study involved measuring EGF-R concentrations in prostate tissues from patients with prostate cancer and benign prostatic hyperplasia using biochemical assays.
Limitations
The study did not include patients who had received any therapy prior to entry, which may limit the generalizability of the findings.
Participant Demographics
Patients aged between 57 and 85 years, with 19 having prostate cancer and 18 having benign prostatic hyperplasia.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website